香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 須予披露交易 完成收購目標公司 茲提述本公司日期為二零二五年二月二十一日有關收購目標公司的公告（「該 公 告」）。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 董 事 會 欣 然 宣 佈，買 賣 協 議 的 所 有 條 件 已 獲 達 成，且 完 成 已 根 據 買 賣 協 議 於 二 零 二 五 年 四 月 三 日 落 實。於 完 成 後，本 公 司 間 接 擁 有 目 標 公 司90%的 權 益，以 及 目 標 公 司 成 為 本 公 司 的 非 全 資 附 屬 公 司，而 其 財 務 業 績 將 於 本 集 團 的 財 務 報 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因本聯合公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何 損 失 承 擔 任 何 責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） JBM (Healthcare) Limited 健倍 苗 苗 ( 保健 ) 有 限 公司 （於開曼群島註冊成立的有限公司） （股份 代號：2161） 聯合公告 關連交易 及 持續關連交易 二零二五年許可協議 二零二五年許可協議 於 二 零 二 五 年 二 月 二 十 八 日，歐 化 藥 業 與 李 衆 勝 堂 訂 立 二 零 二 五 年 許 可 協 議，據 此，歐 化 藥 業 同 意 根 據 二 零 二 五 年 許 可 協 議 的 條 款 及 條 件 許 可 李 衆 勝 堂 使 用 部 分 工 廠，年 期 自 二 零 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 （於開曼群島註冊成立的有限公司） ( ) 買賣協議 日 期 （股份代號：2161） 須予披露交易 收購目標公司 收購事項 於二零二五年二月二十一日（交 易 時 段 後），買 方（本 公 司 的 間 接 全 資 附 屬 公 司）與 賣 方 訂 立 買 賣 協 議，據 此，買 方 有 條 件 同 意 收 購 而 賣 方 有 條 件 同 意 出 售銷售股份（佔 目 標 公 司 已 發 行 股 本 的90%），根 據 買 賣 協 議 的 條 款 及 條 件， 總代價為171,000,000港 元。 上市規則的涵義 由於有關收購事項的一項或多項適用百分比率高於5%，但 所 有 有 關 比 率 均 低 於25%，故 根 據 上 市 規 則 第 十 四 章，收 購 事 項 構 成 ...

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) Dear Non-registered Shareholder(s)(Note 1), JBM (Healthcare) Limited (the "Company") – Notice of publication of 2024/2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.jbmhealthcare.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk respectively (the "Website Version"). The Company strongly rec ...

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) (Incorporated in the Cayman Islands with limited liability) (Stock Code 股份代號：2161) （於開曼群島註冊成立的有限公司） NOTIFICATION LETTER 通知信函 13 December 2024 Dear Registered Shareholder(s), JBM (Healthcare) Limited (the "Company") It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by com ...

Financial Performance - Total revenue for the six months ended September 30, 2024, was HKD 398,953,000, representing a 22.1% increase from HKD 326,828,000 in the same period of 2023[5]. - Gross profit for the period was HKD 205,888,000, up 20.3% from HKD 171,122,000, with a gross margin of 51.6%[5]. - Profit attributable to equity holders increased by 53.5% to HKD 95,881,000, with a profit margin of 24.0%[5]. - Adjusted EBITDA rose by 31.8% to HKD 144,059,000, with an adjusted EBITDA margin of 36.1%[5][7]. - Operating profit surged by HKD 35.8 million or 41.7% to HKD 121.6 million, primarily due to an increase in gross profit[47]. - Net profit attributable to equity holders rose by 53.4% to HKD 95.9 million[19]. - Basic and diluted earnings per share rose to HKD 11.63, compared to HKD 6.87 in the same period last year[110]. Revenue Breakdown - Brand medicine revenue increased by 23.8% to HKD 130,658,000, while brand Chinese medicine revenue rose by 17.9% to HKD 219,701,000[5]. - Health supplements revenue surged by 39.0% to HKD 48,594,000, indicating strong demand in this segment[5]. - The brand pharmaceutical segment saw a growth of 23.9%, attributed to effective brand marketing and sales support for He Ji Gong products[37]. - The brand Chinese medicine segment grew by 17.9%, driven by strong performance of Baoji Pills and the ongoing growth of concentrated Chinese medicine granules[37]. - Oncotype DX, a breast cancer gene expression test, achieved a revenue growth of 38.9%, gaining widespread recognition among hospitals and healthcare professionals in Hong Kong and Macau[24]. Market Strategy and Expansion - The company aims to enhance personal health management through self-care products and solutions, positioning itself as a leading healthcare partner in Asia[11]. - The company is committed to developing new health products and expanding its market presence to meet growing consumer demand[11]. - The company successfully implemented an integrated online and offline sales and marketing strategy, capitalizing on growth opportunities in the consumer healthcare market in Hong Kong, Macau, and the Greater Bay Area[20]. - The company is strategically expanding its brand products in the Greater Bay Area to capture the growing demand for traditional Chinese medicine[29]. - The company is increasing investments in digital marketing to enhance its appeal to younger consumers, particularly on platforms like Xiaohongshu and Douyin[24]. Financial Position - Total assets as of September 30, 2024, were HKD 1,409,493,000, reflecting a 1.5% increase from HKD 1,388,697,000[6]. - Total liabilities decreased by 6.5% to HKD 342,796,000, while total equity increased by 4.4% to HKD 1,066,697,000[6]. - The company has a robust financial position with strong cash reserves, supporting current operations and future development plans[20]. - The company maintained a conservative capital management approach, ensuring a solid foundation for future business development and potential acquisitions[60]. Shareholder Information - The interim dividend declared for the six months ending September 30, 2024, is HKD 0.055 per share, totaling approximately HKD 45.2 million, compared to HKD 0.0345 per share and HKD 31.0 million for the same period last year[81]. - As of September 30, 2024, Mr. Chan holds 62.39% of the company's issued share capital, representing 512,823,346 shares[83]. - The company repurchased a total of 12,148,000 shares at an approximate cost of HKD 11.9 million during the six months ending September 30, 2024[78]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance codes and regulations during the reporting period[76]. - The board of directors consists of three independent non-executive directors, ensuring high standards of corporate governance[79]. - There were no significant regulatory non-compliance issues related to applicable environmental laws and regulations during the reporting period[72]. - The company has implemented various measures to promote environmental sustainability and energy conservation[74]. Employee and Operational Insights - The workforce increased to 279 employees, with total employee costs amounting to approximately HKD 52.9 million[32]. - Employee costs rose by HKD 5.1 million or 30.0%, mainly due to increased production of proprietary brand products to meet market demand[42]. - The company is committed to enhancing operational excellence and growth strategies, focusing on product diversification and expanding sales platforms[31]. Cash Flow and Investments - Cash generated from operating activities increased significantly to HKD 134,598,000, compared to HKD 62,913,000 in the prior year, representing a growth of approximately 114%[118]. - The company reported a net cash outflow from investing activities of HKD 4,667,000, an improvement from HKD 9,045,000 in the previous year, indicating a reduction of about 48%[118]. - Financing activities resulted in a net cash outflow of HKD 111,198,000, compared to HKD 88,816,000 in the previous year, reflecting an increase of approximately 25%[118]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[120]. - The company is actively pursuing strategic acquisitions to enhance its product offerings and market reach[120].

EF001 免責聲明 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會由主席兼非執行董事岑廣業先生；執行董事黃一偉先生（亦為行政總裁）及鄭香郡博士；非執行董事嚴振亮 第 2 頁 共 2 頁 v 1.1.1 先生及楊國晉先生；以及獨立非執行董事陳錦釗先生、陸庭龍先生及劉述理先生組成。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 健倍苗苗(保健 )有限公司 | | 股份代號 | 02161 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二四年九月三十日止六個月的中期股息 | | 公告日期 | 2024年11月19日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年3月 ...

Financial Performance - For the six months ended September 30, 2024, revenue was approximately HKD 399.0 million, an increase of about 22.1% compared to HKD 326.8 million in the same period of 2023[2]. - Operating profit for the same period was approximately HKD 121.6 million, up about 41.7% from HKD 85.8 million in 2023[2]. - Profit attributable to equity holders of the company was approximately HKD 95.9 million, representing a 53.4% increase from HKD 62.5 million in the previous year[2]. - The total comprehensive income for the period was HKD 95.0 million, compared to HKD 61.9 million in the same period of 2023[4]. - Basic and diluted earnings per share for the period were HKD 11.63, compared to HKD 6.87 in the previous year[7]. - The group reported external customer revenue of HKD 398,953 thousand for the six months ended September 30, 2024, compared to HKD 326,828 thousand for the same period in 2023, representing a growth of approximately 22%[25]. - The gross profit for the reportable segments was HKD 205,888 thousand for the six months ended September 30, 2024, up from HKD 171,122 thousand in 2023, indicating an increase of about 20%[26]. - The adjusted EBITDA for the group was HKD 144,059 thousand for the six months ended September 30, 2024, compared to HKD 109,288 thousand in 2023, reflecting a growth of approximately 32%[26]. - The health supplement segment reported revenue of HKD 48,594 thousand for the six months ended September 30, 2024, up from HKD 34,967 thousand in 2023, which is an increase of approximately 39%[25]. - The group’s healthcare business recorded revenue of HKD 399.0 million, an increase of 22.1% compared to the previous period[56]. - Gross profit increased to HKD 205.9 million, reflecting a growth of 20.3% year-on-year[56]. - Net profit attributable to equity holders rose by 53.4% to HKD 95.9 million[56]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.055 per share, totaling approximately HKD 45.2 million, a 59.4% increase from HKD 0.0345 per share (totaling HKD 31.0 million) in the same period last year[2]. - The interim dividend declared was HKD 5.50 per share, up from HKD 3.45 per share in the previous year, totaling HKD 45,210,000 compared to HKD 30,959,000[42]. - The board has approved a share buyback program worth HKD 200 million to enhance shareholder value and support stock price stability[144]. Assets and Liabilities - Non-current assets as of September 30, 2024, amounted to HKD 1,006.0 million, a slight decrease from HKD 1,021.2 million as of March 31, 2024[9]. - Current assets totaled HKD 403.4 million, an increase from HKD 367.5 million as of March 31, 2024[9]. - Current liabilities were HKD 243.9 million, compared to HKD 221.6 million in the previous period[9]. - Total equity attributable to equity holders of the company was HKD 1,012.0 million, up from HKD 970.7 million as of March 31, 2024[12]. - The total non-current assets as of September 30, 2024, amounted to HKD 998,546,000, a slight decrease from HKD 1,009,150,000 as of March 31, 2024[30]. - As of September 30, 2024, trade payables amounted to HKD 17,033 million, a decrease of 23.5% from HKD 22,171 million on March 31, 2024[1]. - Other payables and accrued expenses increased to HKD 87,494 million from HKD 80,538 million, reflecting a growth of 8.1%[1]. - As of September 30, 2024, bank loans decreased from HKD 115.0 million on March 31, 2024, to HKD 70.0 million, due to partial repayment of bank loans[114]. - The net capital debt ratio was zero as of September 30, 2024, indicating no bank loans after accounting for cash and cash equivalents[117]. Costs and Expenses - The group’s financing costs decreased to HKD 2,936 thousand for the six months ended September 30, 2024, from HKD 4,138 thousand in 2023, showing a reduction of about 29%[26]. - The net other income for the group was a loss of HKD 56,966 thousand for the six months ended September 30, 2024, compared to a loss of HKD 66,961 thousand in 2023, indicating an improvement[26]. - The group’s administrative and other operating expenses increased to HKD 36,941 thousand for the six months ended September 30, 2024, from HKD 25,273 thousand in 2023, representing an increase of approximately 46%[26]. - Employee costs totaled approximately HKD 52.9 million, with a notable increase of 30.0% in employee costs from the previous year[81][98]. - Material costs accounted for approximately 81% of total sales costs, remaining stable compared to the previous period[98]. Market and Strategic Initiatives - The retail environment remains challenging, but the company achieved significant results due to its rich product portfolio and strong brand management[54]. - The company strategically focuses on core growth plans to strengthen its position in the brand healthcare market[55]. - The company is enhancing its digital marketing investments, particularly on platforms like Xiaohongshu and Douyin, to attract younger consumers[62]. - The company is strategically enhancing its brand presence in mainland China by establishing flagship stores on Tmall International for various products, significantly improving brand image and recognition among Chinese consumers[71]. - The company plans to expand its market presence in the Greater Bay Area, targeting a 25% increase in market share within the next two years[144]. - A strategic acquisition of a local herbal product company is anticipated to enhance the company's product portfolio and is expected to close by Q1 2025[144]. Corporate Governance and Compliance - The company has complied with all applicable laws and regulations in all material aspects during the reporting period[131]. - The board emphasizes the importance of high standards of corporate governance to protect shareholder interests and enhance corporate value[132]. - The company has adopted the corporate governance code as its own governance principles and has complied with all relevant provisions[133]. - The audit committee consists of three independent non-executive directors, responsible for overseeing the integrity of the company's financial statements[137]. - The interim results have been reviewed by an independent auditor, with no reservations noted in the review report[138]. Future Outlook - The company expects to achieve a revenue growth target of 10% for the fiscal year 2025, driven by new product launches and market expansion strategies[144]. - Research and development efforts have led to the introduction of three new herbal medicine products, which are expected to contribute an additional HKD 50 million in revenue by the end of fiscal year 2025[144]. - The company has allocated HKD 100 million for technology upgrades to enhance production efficiency and product quality in the upcoming fiscal year[144]. - The company maintains a positive outlook for long-term growth, supported by increasing health awareness and government policies favoring traditional Chinese medicine[78].

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因本聯合公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何 損 失 承 擔 任 何 責 任。 Pharma Corporation Jacobson Pharma Corporation Limited 雅 各 臣 科 研 製 藥 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2633） JBM (Healthcare) Limited 健倍 苗 苗 ( 保健 ) 有 限 公司 （於開曼群島註冊成立的有限公司） （股份 代號：2161） 聯合公告 有關買賣 李衆勝堂（集 團）有限公司 股份的關連交易 買賣李衆勝堂（集 團）有限公司股份 於二零二四年十一月十一日（交 易 時 段 後），Po Chai Herbal 及 PCHT（作 為 賣 方）與歐化藥業（作 為 買 方）訂 立 買 賣 協 議，據 此，Po Chai Herbal 及 PCHT 有 條 件同意分別出售56,500股 及44,000股 銷 售 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) （於開曼群島註冊成立的有限公司） （股份代號：2161） 健倍苗苗（保 健）有限公司（「本公司」）董事會（「董事會」）兹通告謹定於二零二四 年十一月十九日（星 期 二）舉 行 董 事 會 會 議，藉 以 考 慮 及 通 過 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 九 月 三 十 日 止 的 六 個 月 中 期 業 績 以 供 發 佈，並 考 慮 建 議 派 發中期股息（如 有），以 及 處 理 其 他 事 項。 承董事會命 健倍苗苗（保 健）有限公司 公司秘書 余振球 香 港，二 零 二 四 年 十 一 月 四 日 於 本 公 告 日 期，董 事 會 由 主 席 兼 非 執 行 董 事 岑 廣 業 先 生；執 行 董 事 黃 一 偉 ...